Cinchonan-6',9-diol--hydrogen chloride (1/1) | 72436-12-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 英文名称: Cinchonan-6',9-diol--hydrogen chloride (1/1)
• 英文别名: 4-[(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-hydroxymethyl]quinolin-6-ol;hydrochloride
• CAS: 72436-12-5
• 化学式: C19H23ClN2O2
• 分子量: 346.8
• InChiKey: PSXDRNCJTBOUPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.54
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  57.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] DOPAMINE-B-HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DOPAMINE-B-HYDROXYLASE
  申请人：BIAL PORTELA & Cª S A

  公开号：WO2018056855A1

  公开（公告）日：2018-03-29

  This invention relates to: (a) compounds of Formula Ia (with R1, R4, R5, R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

  本发明涉及：(a) 公式Ia中的化合物（其中R1、R4、R5、R6、n和A如本文所定义），以及作为多巴胺-β-羟化酶抑制剂的药用盐或溶剂；(b) 包含这些化合物、盐或溶剂的药物组合物；(c) 使用这些化合物、盐或溶剂进行治疗；(d) 使用这些化合物、盐或溶剂进行治疗的治疗方法；以及(e) 用于合成这些化合物的过程和中间体。
• Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors
  申请人：BIAL—PORTELA & Cᵃ, S.A.

  公开号：US10975083B2

  公开（公告）日：2021-04-13

  This invention relates to: (a) compounds of formula (I) (with R1 to R5, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

  本发明涉及：(a) 可用作多巴胺-β-羟化酶抑制剂的式 (I) 化合物（其中 R1 至 R5、n 和 A 如本文所定义）及其药学上可接受的盐或溶液；(b) 包含此类化合物、盐或溶液的药物组合物；(c) 此类化合物、盐或溶液在治疗中的用途；(d) 使用此类化合物、盐或溶液的治疗方法；以及 (e) 用于合成此类化合物的工艺和中间体。
• Dopamine-β-hydroxylase inhibitors
  申请人：BIAL—PORTELA & Ca, S.A.

  公开号：US11034695B2

  公开（公告）日：2021-06-15

  This invention relates to: (a) compounds of Formula Ia (with R1, R4, R5, R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

  本发明涉及(a) 可用作多巴胺-β-羟化酶抑制剂的式 Ia 化合物（其中 R1、R4、R5、R6、n 和 A 如本文所定义）及其药学上可接受的盐或溶剂；(b) 包含此类化合物、盐或溶剂的药物组合物；(c) 此类化合物、盐或溶剂在治疗中的用途；(d) 使用此类化合物、盐或溶剂的治疗方法；以及 (e) 用于合成此类化合物的工艺和中间体。
• BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS
  申请人：BIAL - PORTELA & Cª, S.A.

  公开号：EP3515433A1

  公开（公告）日：2019-07-31
• DOPAMINE-B-HYDROXYLASE INHIBITORS
  申请人：BIAL - PORTELA & Cª, S.A.

  公开号：EP3515917A1

  公开（公告）日：2019-07-31